Midomafetamine

DB01454IllicitInvestigationalSmall molecule

An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA...

Chemical structure of Midomafetamine
Mechanism
Curator reviewed
Primary indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer.Curator reviewed
Formula / weight
C11H15NO2 · 193.2423 g/mol (avg)
Also known as
3, 4-Methylenedioxymethamphetamine · 3,4 Methylenedioxymethamphetamine · 3,4-Methyl enedioxy methamphetamine · Ecstasy · MDMA

Resolves to

Clinical / RWD
Structure
InChIKeySHXWCVYOXRDMCX-UHFFFAOYSA-NSMILESCNC(C)CC1=CC2=C(OCO2)C=C1

What you can answer from here — as of September 16, 2026

9Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,471Drug interactionsStructured to mechanism, not free text
Sign in
59Clinical trialsPhase, status and sponsor resolved per trial
Sign in
43+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Midomafetamine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account